Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?

Groupe de Recherche en Reanimation Respiratoire du patient d’Onco-Hématologie (Grrr-OH)

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Checkpoint protein inhibitor antibodies (CPI), including cytotoxic T-lymphocyte-associated antigen 4 inhibitors (ipilimumab, tremelimumab) and the programmed cell death protein 1 pathway/programmed cell death protein 1 ligand inhibitors (pembrolizumab, nivolumab, durvalumab, atezolizumab), have entered routine practice for the treatment of many cancers. They improve the outcome for many cancers, and more patients will be treated with CPI in the future. Although CPI can lead to adverse events (AE) less frequently than for chemotherapy, their use can require intensive care unit admission in case of severe immune-related adverse events (IrAE). Moreover, some of these events, particularly late events, are poorly documented, so a high level of suspicion should be maintained for patients receiving CPI. Intensivists should be aware in general of the known complications and appropriate management of these AE. Nevertheless, a multidisciplinary collaboration remains essential for their diagnosis and management. This review described the most severe complications related to CPI.

Original languageEnglish (US)
Article number25
JournalAnnals of Intensive Care
Volume9
Issue number1
DOIs
StatePublished - Dec 1 2019

Fingerprint

Critical Care
Physicians
Antibodies
Proteins
CD274 Antigen
CTLA-4 Antigen
Apoptosis Regulatory Proteins
Intensive Care Units
Neoplasms
Drug Therapy
Therapeutics

All Science Journal Classification (ASJC) codes

  • Critical Care and Intensive Care Medicine

Cite this

Groupe de Recherche en Reanimation Respiratoire du patient d’Onco-Hématologie (Grrr-OH) (2019). Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know? Annals of Intensive Care, 9(1), [25]. https://doi.org/10.1186/s13613-019-0487-x
Groupe de Recherche en Reanimation Respiratoire du patient d’Onco-Hématologie (Grrr-OH). / Severe toxicity from checkpoint protein inhibitors : What intensive care physicians need to know?. In: Annals of Intensive Care. 2019 ; Vol. 9, No. 1.
@article{aa90e3f01ec04c3e944016740aed7b67,
title = "Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?",
abstract = "Checkpoint protein inhibitor antibodies (CPI), including cytotoxic T-lymphocyte-associated antigen 4 inhibitors (ipilimumab, tremelimumab) and the programmed cell death protein 1 pathway/programmed cell death protein 1 ligand inhibitors (pembrolizumab, nivolumab, durvalumab, atezolizumab), have entered routine practice for the treatment of many cancers. They improve the outcome for many cancers, and more patients will be treated with CPI in the future. Although CPI can lead to adverse events (AE) less frequently than for chemotherapy, their use can require intensive care unit admission in case of severe immune-related adverse events (IrAE). Moreover, some of these events, particularly late events, are poorly documented, so a high level of suspicion should be maintained for patients receiving CPI. Intensivists should be aware in general of the known complications and appropriate management of these AE. Nevertheless, a multidisciplinary collaboration remains essential for their diagnosis and management. This review described the most severe complications related to CPI.",
author = "{Groupe de Recherche en Reanimation Respiratoire du patient d’Onco-H{\'e}matologie (Grrr-OH)} and Virginie Lemiale and Meert, {Anne Pascale} and Fran{\cc}ois Vincent and Michael Darmon and Bauer, {Philippe R.} and {Van de Louw}, Andry and Elie Azoulay",
year = "2019",
month = "12",
day = "1",
doi = "10.1186/s13613-019-0487-x",
language = "English (US)",
volume = "9",
journal = "Annals of Intensive Care",
issn = "2110-5820",
publisher = "Springer-Verlag GmbH and Co. KG",
number = "1",

}

Groupe de Recherche en Reanimation Respiratoire du patient d’Onco-Hématologie (Grrr-OH) 2019, 'Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?', Annals of Intensive Care, vol. 9, no. 1, 25. https://doi.org/10.1186/s13613-019-0487-x

Severe toxicity from checkpoint protein inhibitors : What intensive care physicians need to know? / Groupe de Recherche en Reanimation Respiratoire du patient d’Onco-Hématologie (Grrr-OH).

In: Annals of Intensive Care, Vol. 9, No. 1, 25, 01.12.2019.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Severe toxicity from checkpoint protein inhibitors

T2 - What intensive care physicians need to know?

AU - Groupe de Recherche en Reanimation Respiratoire du patient d’Onco-Hématologie (Grrr-OH)

AU - Lemiale, Virginie

AU - Meert, Anne Pascale

AU - Vincent, François

AU - Darmon, Michael

AU - Bauer, Philippe R.

AU - Van de Louw, Andry

AU - Azoulay, Elie

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Checkpoint protein inhibitor antibodies (CPI), including cytotoxic T-lymphocyte-associated antigen 4 inhibitors (ipilimumab, tremelimumab) and the programmed cell death protein 1 pathway/programmed cell death protein 1 ligand inhibitors (pembrolizumab, nivolumab, durvalumab, atezolizumab), have entered routine practice for the treatment of many cancers. They improve the outcome for many cancers, and more patients will be treated with CPI in the future. Although CPI can lead to adverse events (AE) less frequently than for chemotherapy, their use can require intensive care unit admission in case of severe immune-related adverse events (IrAE). Moreover, some of these events, particularly late events, are poorly documented, so a high level of suspicion should be maintained for patients receiving CPI. Intensivists should be aware in general of the known complications and appropriate management of these AE. Nevertheless, a multidisciplinary collaboration remains essential for their diagnosis and management. This review described the most severe complications related to CPI.

AB - Checkpoint protein inhibitor antibodies (CPI), including cytotoxic T-lymphocyte-associated antigen 4 inhibitors (ipilimumab, tremelimumab) and the programmed cell death protein 1 pathway/programmed cell death protein 1 ligand inhibitors (pembrolizumab, nivolumab, durvalumab, atezolizumab), have entered routine practice for the treatment of many cancers. They improve the outcome for many cancers, and more patients will be treated with CPI in the future. Although CPI can lead to adverse events (AE) less frequently than for chemotherapy, their use can require intensive care unit admission in case of severe immune-related adverse events (IrAE). Moreover, some of these events, particularly late events, are poorly documented, so a high level of suspicion should be maintained for patients receiving CPI. Intensivists should be aware in general of the known complications and appropriate management of these AE. Nevertheless, a multidisciplinary collaboration remains essential for their diagnosis and management. This review described the most severe complications related to CPI.

UR - http://www.scopus.com/inward/record.url?scp=85060914507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060914507&partnerID=8YFLogxK

U2 - 10.1186/s13613-019-0487-x

DO - 10.1186/s13613-019-0487-x

M3 - Review article

C2 - 30707321

AN - SCOPUS:85060914507

VL - 9

JO - Annals of Intensive Care

JF - Annals of Intensive Care

SN - 2110-5820

IS - 1

M1 - 25

ER -

Groupe de Recherche en Reanimation Respiratoire du patient d’Onco-Hématologie (Grrr-OH). Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know? Annals of Intensive Care. 2019 Dec 1;9(1). 25. https://doi.org/10.1186/s13613-019-0487-x